Lipocine Inc. (LPCN) P/E Ratio History
Deep ValueTrading at -1.2x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2022–2022
Loading P/E history...
P/E Ratio Analysis
As of September 24, 2026, Lipocine Inc. (LPCN) trades at a price-to-earnings ratio of -1.2x, with a stock price of $2.09 and trailing twelve-month earnings per share of $-1.44.
The current P/E is 106% below its 5-year average of 20.0x. Over the past five years, LPCN's P/E has ranged from a low of 11.1x to a high of 29.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, LPCN trades at a 105% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 164.5x.
Relative to the broader market, LPCN trades at a notable discount to the S&P 500 median P/E of 24.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LPCN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
LPCN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
LPCN P/E vs Peers
Metabolic and Obesity Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 22.3Lowest | - | +419%Best | |
| $468B | 111.8 | - | -1% | |
| $1B | 164.5 | - | -79% | |
| $45B | 35.1 | 0.87Best | +5% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
LPCN Historical P/E Data (2022–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q3 | Sep 30 2022 | $7.65 | $0.69 | 11.1x | -45% |
| FY2022 Q2 | - | $13.62 | $0.47 | 29.0x | +45% |
Average P/E for displayed period: 20.0x
LPCN Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LPCN — Frequently Asked Questions
Quick answers to the most common questions about buying LPCN stock.
What is LPCN's P/E ratio?
Lipocine Inc. (LPCN) trailing twelve-month P/E ratio is -1.2x, based on TTM diluted EPS of $-1.44. The 5-year average P/E is 20.0x and the historical range spans 11.1x to 29.0x.
Is LPCN stock overvalued or undervalued?
LPCN trades at -1.2x P/E, below its 5-year average of 20.0x. At the 0th percentile of its historical range (11.1x–29.0x), the stock is priced at a discount to its own history.
Is LPCN stock expensive?
No, LPCN is not expensive on a historical basis. The current P/E of -1.2x is below the 5-year average of 20.0x and sits at the 0th percentile of its valuation range.
What is LPCN's historical P/E range?
Over the past 5 years, LPCN's P/E ratio has ranged from 11.1x to 29.0x, with a median of 29.0x and an average of 20.0x. The current P/E of -1.2x places the stock at the 0th percentile of this range. Full historical data spans 2022–2022.
How does LPCN's P/E compare to the S&P 500?
LPCN trades at -1.2x P/E versus the S&P 500 median of 24.8x. The 105% discount to the market suggests lower growth expectations or perceived higher risk.
How does LPCN's valuation compare to Healthcare peers?
Lipocine Inc. P/E of -1.2x compares to the Healthcare sector median of 23.7x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is LPCN's PEG ratio?
LPCN PEG ratio is N/A. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is LPCN's earnings yield?
LPCN earnings yield is N/A, the inverse of its -1.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.